SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer
Figure 2.(A–R) mRNA expression levels of SLC family members in ovarian cancer (426 samples) and normal ovarian tissues (88 samples) (GEPIA). *P < 0.01. SLC, solute carrier.